Glycemic control is independently associated with rapid progression of coronary atherosclerosis in the absence of a baseline coronary plaque burden: a retrospective case-control study from the PARADIGM registry.
Humans
Male
Middle Aged
Aged
Female
Plaque, Atherosclerotic
Coronary Artery Disease
/ diagnostic imaging
Retrospective Studies
Coronary Angiography
/ methods
Case-Control Studies
Glycemic Control
Glycated Hemoglobin
Prospective Studies
Disease Progression
Computed Tomography Angiography
/ methods
Coronary Vessels
/ diagnostic imaging
Registries
Predictive Value of Tests
Coronary artery disease
Coronary computed tomography angiography
Hemoglobin A1c
Progression
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
12 11 2022
12 11 2022
Historique:
received:
18
07
2022
accepted:
26
09
2022
entrez:
12
11
2022
pubmed:
13
11
2022
medline:
16
11
2022
Statut:
epublish
Résumé
The baseline coronary plaque burden is the most important factor for rapid plaque progression (RPP) in the coronary artery. However, data on the independent predictors of RPP in the absence of a baseline coronary plaque burden are limited. Thus, this study aimed to investigate the predictors for RPP in patients without coronary plaques on baseline coronary computed tomography angiography (CCTA) images. A total of 402 patients (mean age: 57.6 ± 10.0 years, 49.3% men) without coronary plaques at baseline who underwent serial coronary CCTA were identified from the Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging (PARADIGM) registry and included in this retrospective study. RPP was defined as an annual change of ≥ 1.0%/year in the percentage atheroma volume (PAV). During a median inter-scan period of 3.6 years (interquartile range: 2.7-5.0 years), newly developed coronary plaques and RPP were observed in 35.6% and 4.2% of the patients, respectively. The baseline traditional risk factors, i.e., advanced age (≥ 60 years), male sex, hypertension, diabetes mellitus, hyperlipidemia, obesity, and current smoking status, were not significantly associated with the risk of RPP. Multivariate linear regression analysis showed that the serum hemoglobin A1c level (per 1% increase) measured at follow-up CCTA was independently associated with the annual change in the PAV (β: 0.098, 95% confidence interval [CI]: 0.048-0.149; P < 0.001). The multiple logistic regression models showed that the serum hemoglobin A1c level had an independent and positive association with the risk of RPP. The optimal predictive cut-off value of the hemoglobin A1c level for RPP was 7.05% (sensitivity: 80.0%, specificity: 86.7%; area under curve: 0.816 [95% CI: 0.574-0.999]; P = 0.017). In this retrospective case-control study, the glycemic control status was strongly associated with the risk of RPP in patients without a baseline coronary plaque burden. This suggests that regular monitoring of the glycemic control status might be helpful for preventing the rapid progression of coronary atherosclerosis irrespective of the baseline risk factors. Further randomized investigations are necessary to confirm the results of our study. ClinicalTrials.gov NCT02803411.
Sections du résumé
BACKGROUND
The baseline coronary plaque burden is the most important factor for rapid plaque progression (RPP) in the coronary artery. However, data on the independent predictors of RPP in the absence of a baseline coronary plaque burden are limited. Thus, this study aimed to investigate the predictors for RPP in patients without coronary plaques on baseline coronary computed tomography angiography (CCTA) images.
METHODS
A total of 402 patients (mean age: 57.6 ± 10.0 years, 49.3% men) without coronary plaques at baseline who underwent serial coronary CCTA were identified from the Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging (PARADIGM) registry and included in this retrospective study. RPP was defined as an annual change of ≥ 1.0%/year in the percentage atheroma volume (PAV).
RESULTS
During a median inter-scan period of 3.6 years (interquartile range: 2.7-5.0 years), newly developed coronary plaques and RPP were observed in 35.6% and 4.2% of the patients, respectively. The baseline traditional risk factors, i.e., advanced age (≥ 60 years), male sex, hypertension, diabetes mellitus, hyperlipidemia, obesity, and current smoking status, were not significantly associated with the risk of RPP. Multivariate linear regression analysis showed that the serum hemoglobin A1c level (per 1% increase) measured at follow-up CCTA was independently associated with the annual change in the PAV (β: 0.098, 95% confidence interval [CI]: 0.048-0.149; P < 0.001). The multiple logistic regression models showed that the serum hemoglobin A1c level had an independent and positive association with the risk of RPP. The optimal predictive cut-off value of the hemoglobin A1c level for RPP was 7.05% (sensitivity: 80.0%, specificity: 86.7%; area under curve: 0.816 [95% CI: 0.574-0.999]; P = 0.017).
CONCLUSION
In this retrospective case-control study, the glycemic control status was strongly associated with the risk of RPP in patients without a baseline coronary plaque burden. This suggests that regular monitoring of the glycemic control status might be helpful for preventing the rapid progression of coronary atherosclerosis irrespective of the baseline risk factors. Further randomized investigations are necessary to confirm the results of our study.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02803411.
Identifiants
pubmed: 36371222
doi: 10.1186/s12933-022-01656-9
pii: 10.1186/s12933-022-01656-9
pmc: PMC9655903
doi:
Substances chimiques
Glycated Hemoglobin A
0
Banques de données
ClinicalTrials.gov
['NCT02803411']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
239Informations de copyright
© 2022. The Author(s).
Références
JAMA Cardiol. 2021 Nov 1;6(11):1257-1266
pubmed: 34406326
Cardiovasc Diabetol. 2020 Jul 18;19(1):113
pubmed: 32682451
J Am Coll Cardiol. 2013 Jul 30;62(5):460-7
pubmed: 23727206
JACC Cardiovasc Imaging. 2013 Jan;6(1):86-95
pubmed: 23328566
Eur Heart J. 2014 Nov 7;35(42):2960-71
pubmed: 25062951
Sci Rep. 2020 Dec 7;10(1):21324
pubmed: 33288827
JACC Cardiovasc Imaging. 2015 Aug;8(8):900-9
pubmed: 26189116
Am Heart J. 2016 Dec;182:72-79
pubmed: 27914502
Circulation. 2018 Feb 13;137(7):665-679
pubmed: 29142010
Circ Res. 2015 Jun 19;117(1):99-104
pubmed: 26089367
J Am Coll Cardiol. 2014 Apr 29;63(16):1604-16
pubmed: 24583311
Circulation. 1999 Aug 31;100(9):903-9
pubmed: 10468519
Atherosclerosis. 2021 May;324:46-51
pubmed: 33813155
JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484
pubmed: 29909109
BMC Cardiovasc Disord. 2019 Feb 11;19(1):39
pubmed: 30744612
J Am Heart Assoc. 2020 Mar 3;9(5):e013958
pubmed: 32089046
Int J Cardiovasc Imaging. 2013 Jun;29(5):1177-90
pubmed: 23417447
J Am Coll Cardiol. 2013 Jun 4;61(22):2296-305
pubmed: 23562925
JACC Cardiovasc Imaging. 2018 Oct;11(10):1461-1471
pubmed: 29778853
Circulation. 2011 Aug 16;124(7):779-88
pubmed: 21788584
J Am Coll Cardiol. 2021 Jun 8;77(22):2777-2791
pubmed: 34082907
Eur Radiol. 2015 Oct;25(10):3073-83
pubmed: 25994190
J Am Coll Cardiol. 2010 May 25;55(21):2399-407
pubmed: 20488313
Cardiovasc Diabetol. 2020 Mar 16;19(1):34
pubmed: 32178666
J Cardiovasc Comput Tomogr. 2016 Nov - Dec;10(6):435-449
pubmed: 27780758
Cardiovasc Diabetol. 2019 Sep 24;18(1):123
pubmed: 31551077
J Cardiovasc Comput Tomogr. 2014 Sep-Oct;8(5):342-58
pubmed: 25301040
Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64
pubmed: 29222377
Korean Circ J. 2019 May;49(5):448-457
pubmed: 30808082
Eur Heart J. 2008 Oct;29(19):2373-81
pubmed: 18682447